ShangPharma Innovation

Rila Therapeutics is a biotherapeutics company dedicated to developing innovative treatments for chronic fibrotic diseases, with a particular emphasis on renal fibrosis. The company is advancing a first-in-class small molecule allosteric inhibitor that targets HIPK2, aiming to address significant unmet medical needs in the treatment of kidney fibrosis. By focusing on anti-fibrotic therapies, Rila Therapeutics seeks to improve the lives of patients suffering from this condition, offering safe and effective treatment options that can enhance overall patient care in the medical community.

Pykus Therapeutics, Inc. is a medical technology company based in Boston, Massachusetts, founded in 2016 by ophthalmology residents. The company specializes in developing a dissolvable intraocular surgical device designed to enhance the experience of patients undergoing retinal surgery. Its innovative polymer-based hydrogel serves as a replacement for traditional intraocular gas, which can impose significant burdens on patients, such as the need for face-down positioning and prolonged periods of visual impairment. By utilizing this biodegradable hydrogel, Pykus Therapeutics aims to improve surgical outcomes and patient comfort, facilitating a faster and more comfortable recovery process after retinal procedures.

Blue Oak Pharmaceuticals is a pharmaceutical company focused on developing innovative treatments for brain disorders. Founded in 2016 and based in Concord, Massachusetts, the company employs a unique drug discovery paradigm that combines custom-designed chemotypes with advanced technologies such as behavioral profiling, synthetic chemistry, and brain imaging. By integrating in vivo phenotypic assays and high-content data analysis, Blue Oak aims to identify first-in-class drugs that target the neurobiology of brain disorders. The company's team of experts collaborates globally with established partners to enhance productivity and drive clinical candidates into early-phase proof-of-concept studies, utilizing translational medicine biomarkers to assess brain circuit activity.

Abcuro, Inc. is a biotechnology company focused on developing immunotherapies for the treatment of autoimmunity and cancer. Based in Newton, Massachusetts, Abcuro creates therapeutic antibodies targeting novel mechanisms related to these diseases. The company utilizes advanced bioinformatics to analyze transcription data from human diseases, which aids in the identification of new therapeutic targets. Through ex-vivo validation in diseased tissues, Abcuro seeks to uncover innovative methods to modulate key components of the immune system. Established in 2015, Abcuro aims to enhance treatment strategies in the healthcare industry by offering effective solutions for complex immunological conditions.

Valitor, Inc. is a biotechnology company founded in 2010 and based in Berkeley, California. The company specializes in developing advanced, protein-based drugs through innovative methods that enhance therapeutic proteins' pharmacokinetics, target specificity, and bioactivity. Valitor's technology platform is versatile, enabling improvements in the pharmacological properties of various existing and emerging protein drugs. The company has established development pipelines in dermatology, ophthalmology, and orthopedics, showcasing its capabilities in creating novel drug products tailored to specific medical needs.

Skyhawk Therapeutics is focused on the discovery and development of small molecule therapeutics aimed at correcting RNA expression. The company utilizes proprietary technology to design small molecules that specifically target binding pocket regions on RNA, ensuring both sequence and structural specificity during critical phases of RNA splicing. This innovative approach enables the development of therapies for various conditions, including cancer, neurological disorders, and rare diseases, particularly those associated with RNA mis-splicing known as exon skipping. Founded in 2015 and headquartered in Waltham, Massachusetts, Skyhawk Therapeutics was previously known as Rare Genetix before rebranding in 2018.

Evrys Bio, LLC specializes in the development of innovative antiviral drugs that target sirtuins, proteins that play a vital role in enhancing the body's natural immunity against infections. The company offers a range of antiviral treatments for various conditions, including respiratory syncytial virus, herpes virus, polyomavirus infections, and viral encephalitis. Additionally, Evrys Bio develops therapies for liver infections caused by hepatitis C, hepatitis B, and human cytomegalovirus. Founded on research from Princeton University, the company aims to create first-in-class antivirals that are safe, effective against drug-resistant pathogens, and provide broad-spectrum treatment options. By focusing on the intrinsic immune responses of host cells, Evrys Bio seeks to transform the management of infectious diseases by addressing them holistically rather than targeting specific virus types. Established in 2012 and based in Doylestown, Pennsylvania, the company was previously known as FORGE Life Science, LLC before rebranding in May 2019.

Tilos Therapeutics, Inc. is a biotechnology company focused on developing antibody therapeutics aimed at treating cancer, fibrosis, and related disorders. Founded in 2016 and based in Cambridge, Massachusetts, the company specializes in creating anti-LAP antibodies that target the Latency Associated Peptide of TGF beta, which plays a critical role in regulating immune responses. Tilos Therapeutics primarily concentrates on modulating regulatory T cells and effector cells to enhance the immune system's ability to combat diseases. By leveraging these immunological pathways, Tilos aims to provide innovative treatments that enable patients to initiate therapy more rapidly, ultimately leading to improved medical outcomes.

Rodin Therapeutics is a biotechnology company based in Cambridge, Massachusetts, focused on developing therapeutics for cognitive disorders through the application of epigenetic insights. Founded in 2013 with backing from Atlas Venture and Johnson & Johnson Development Corporation, the company leverages advanced structural biology capabilities and a team experienced in central nervous system (CNS) drug development. Rodin's innovative approach centers on the modulation of histone deacetylase (HDAC) complexes to restore synaptic function and promote neuronal health in degenerative brain diseases. This strategy aims to address significant unmet medical needs in the treatment of neurological disorders. As of November 2019, Rodin operates as a subsidiary of Alkermes Inc.

Quartet Medicine, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative treatments for chronic pain and inflammation. Founded in 2013 by scientists from Boston Children’s Hospital and École Polytechnique Fédérale de Lausanne, Quartet aims to restore tetrahydrobiopterin (BH4) homeostasis in neuronal and inflammatory cells. Research indicates that increased levels of BH4 are essential for regulating peripheral nerve function and immune responses. By leveraging these insights, Quartet is working on novel non-opioid medications that target this biochemical pathway, providing an alternative approach to managing pain and inflammation. The company collaborates with various research partners in Europe and Asia to advance its therapeutic offerings.